Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2021, with the report dated December 1, 2021. The filing serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
| Metric | Value |
|---|---|
| Issued Share Capital (as of Nov 30, 2021) | 5,386,985,162 Ordinary Shares (25 pence each) |
| Treasury Shares | 355,205,950 |
| Total Voting Rights | 5,031,779,212 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely reports the static capital position as of November 30, 2021, to assist shareholders in calculating notification thresholds under FCA rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is strictly administrative regarding share capital and voting rights.
Key Facts for Investor Verification
- Verify the total voting rights denominator of 5,031,779,212 for compliance with FCA disclosure thresholds.
- Confirm the number of treasury shares held is 355,205,950 as of November 30, 2021.
- Note that this filing does not contain financial performance data; refer to Form 20-F for quarterly or annual results.